Detalles de la búsqueda
1.
Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
J Pharmacol Exp Ther
; 384(1): 173-186, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36310034
2.
A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle.
J Biol Chem
; 293(29): 11574-11588, 2018 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29871924
3.
Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.
Drug Metab Dispos
; 47(2): 145-154, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30442651
4.
ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.
BMC Endocr Disord
; 18(1): 24, 2018 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29720169
5.
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
J Pharmacol Exp Ther
; 363(2): 240-252, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28882879
6.
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Biopharm Drug Dispos
; 35(4): 237-52, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24415392
7.
Comparative pharmacokinetics and pharmacodynamics of the advanced Retinol-Binding Protein 4 antagonist in dog and cynomolgus monkey.
PLoS One
; 15(1): e0228291, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31978148
8.
An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.
Drug Metab Dispos
; 37(3): 502-13, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19088267
9.
Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis.
J Med Chem
; 62(11): 5470-5500, 2019 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31079449
10.
Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease.
J Med Chem
; 58(15): 5863-88, 2015 Aug 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-26181715
11.
Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.
J Med Chem
; 57(18): 7731-57, 2014 Sep 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-25210858
12.
Hepatic uptake of the novel antifungal agent caspofungin.
Drug Metab Dispos
; 33(5): 676-82, 2005 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15716364
13.
Study of the fragmentation mechanism of protonated 6-hydroxychlorzoxazone: application in simultaneous analysis of CYP2E1 activity with major human cytochrome P450s.
Anal Chem
; 75(3): 469-78, 2003 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12585472
14.
Mechanistic studies on metabolic interactions between gemfibrozil and statins.
J Pharmacol Exp Ther
; 301(3): 1042-51, 2002 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12023536
15.
Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.
Antimicrob Agents Chemother
; 48(4): 1272-80, 2004 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15047529
16.
Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.
Drug Metab Dispos
; 30(5): 505-12, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-11950779
17.
Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
Drug Metab Dispos
; 32(11): 1254-9, 2004 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15286054
18.
Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
Antimicrob Agents Chemother
; 48(3): 815-23, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14982770
19.
Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins.
Chem Res Toxicol
; 16(2): 198-207, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12588191
20.
Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
J Pharmacol Exp Ther
; 304(3): 1161-71, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12604693